34
Participants
Start Date
February 24, 2020
Primary Completion Date
September 7, 2021
Study Completion Date
September 7, 2021
Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks
Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks.
Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks.
No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks
Participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Empaglizflozin will not be provided to this group.
No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
Participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Empaglizflozin will not be provided to this group.
University of Virginia, Center for Diabetes Technology, Charlottesville
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Tandem Diabetes Care, Inc.
INDUSTRY
DexCom, Inc.
INDUSTRY
Ananda Basu, MD
OTHER